Humanized Antibodies with Anti-Tumor Activity
作者： Philip A. Jennings , Anthony G. Doyle , Norbert Kienzle , Matthew Pollard , Adam W. Clarke
DOI:
关键词:
摘要: The present invention provides humanised antibodies and binding domains thereof with anti-tumor activity. In particular the have specific to direct killing of human colon tumor cells display potent immune-mediated cytotoxic activity against cancer in vitro using antibody-dependent cell-mediated cytotoxicity (ADCC) complement dependent (CDC) assays vivo mouse models.
lens.org参考文章(60)
Robert L. Shields, Jadine Lai, Rodney Keck, Lori Y. O'Connell, Kyu Hong, Y. Gloria Meng, Stefanie H. A. Weikert, Leonard G. Presta, Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity Journal of Biological Chemistry. ,vol. 277, pp. 26733- 26740 ,(2002) , 10.1074/JBC.M202069200
G. A. Lazar, W. Dang, S. Karki, O. Vafa, J. S. Peng, L. Hyun, C. Chan, H. S. Chung, A. Eivazi, S. C. Yoder, J. Vielmetter, D. F. Carmichael, R. J. Hayes, B. I. Dahiyat, Engineered antibody Fc variants with enhanced effector function Proceedings of the National Academy of Sciences of the United States of America. ,vol. 103, pp. 4005- 4010 ,(2006) , 10.1073/PNAS.0508123103
Elizabeth Sally Ward, Immunoglobin-like domains with increased half lives ,(1997)
Gregory P. Winter, Recombinant altered antibodies and methods of making altered antibodies ,(1991)
William F. Dall’ Acqua, Robert M. Woods, E. Sally Ward, Susan R. Palaszynski, Nita K. Patel, Yambasu A. Brewah, Herren Wu, Peter A. Kiener, Solomon Langermann, Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences Journal of Immunology. ,vol. 169, pp. 5171- 5180 ,(2002) , 10.4049/JIMMUNOL.169.9.5171
Deryk Loo, Nancy Pryer, Peter Young, Tony Liang, Suzanne Coberly, Kathleen L. King, Key Kang, Penny Roberts, Mary Tsao, Xiaolin Xu, Beverly Potts, Jennie P. Mather, The glycotope-specific RAV12 monoclonal antibody induces oncosis in vitro and has antitumor activity against gastrointestinal adenocarcinoma tumor xenografts in vivo Molecular Cancer Therapeutics. ,vol. 6, pp. 856- 865 ,(2007) , 10.1158/1535-7163.MCT-06-0581
Claudia Ferrara, Peter Brünker, Tobias Suter, Samuel Moser, Ursula Püntener, Pablo Umaña, Modulation of therapeutic antibody effector functions by glycosylation engineering: Influence of Golgi enzyme localization domain and co‐expression of heterologous β1, 4‐N‐acetylglucosaminyltransferase III and Golgi α‐mannosidase II Biotechnology and Bioengineering. ,vol. 93, pp. 851- 861 ,(2006) , 10.1002/BIT.20777
Andrew J.S. Jones, Damon I. Papac, Edward H. Chin, Rodney Keck, Sharon A. Baughman, Yvonne S. Lin, Johannes Kneer, John E. Battersby, Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys. Glycobiology. ,vol. 17, pp. 529- 540 ,(2007) , 10.1093/GLYCOB/CWM017
William Dall'acqua, Elizabeth Sally Ward, Leslie S. Johnson, Molecules with extended half-lives, compositions and uses thereof ,(2001)
Shiro Nozawa, Daisuke Aoki, Katsumi Tsukazaki, Nobuyuki Susumu, Motoko Sakayori, Nao Suzuki, Atsushi Suzuki, Rie Wakita, Makio Mukai, Yuko Egami, Kyoko Kojima-Aikawa, Isao Ishida, Frederic Belot, Ole Hindsgaul, Minoru Fukuda, Michiko N. Fukuda, HMMC-1: A Humanized Monoclonal Antibody With Therapeutic Potential Against Müllerian Duct-Related Carcinomas Clinical Cancer Research. ,vol. 10, pp. 7071- 7078 ,(2004) , 10.1158/1078-0432.CCR-04-0802